**G627 STUDY TO INVESTIGATE THE EFFECTIVENESS OF USING A HUMANOID ROBOT (KASPAR) TO IMPROVE THE SOCIAL SKILLS OF CHILDREN WITH AN AUTISM SPECTRUM DISORDER (ASD): A RANDOMISED CONTROLLED FEASIBILITY TRIAL**

1K Irvine, 5S Menguni, 0D Thakur, 5S Sharma. 1Department of Psychology and Sport Sciences, University of Hertfordshire, Hatfield, UK; 2Department of Community Paediatrics, Hertfordshire Community NHS Trust, Welwyn Garden City, UK

Aims A growing body of research has shown that robots can be effective in improving the social communication skills of children with ASD, however randomised controlled trials (RCTs) are lacking. This feasibility RCT examined whether it is possible to deliver a social skills intervention using the Kaspar robot with children with ASD within the NHS.

Method Children with ASD aged between 5–10 took part in six therapy sessions targeting key social communication skills with a therapist. Children were randomised to therapy using the robot or with the therapist only. Parental stress and the child’s social skills were assessed at three time points, using parent-reported questionnaires and video analysis.

Results The criteria for recruitment and data collection were met. Forty-five percent of those sent details of the study (42/94) agreed to take part. Of these, 38 were randomised and a further seven withdrew post-randomisation: an attrition rate of 26%. More than 80% of the questionnaires were completed. Some technical issues arose, which could be addressed in a full-scale study. Feedback from parents and clinicians was positive.

Conclusion The findings confirm the feasibility of a full-scale trial to determine whether Kaspar is an effective social skills intervention for children with ASD in an NHS setting.

**G628 A RETROSPECTIVE STUDY TO UNDERSTAND EMERGING THEMES FROM USING LONG-ACTING GUANFACINE – NON STIMULANT MEDICATION IN 70 CHILDREN AND YOUNG PEOPLE WITH ADHD (ATTENTION DEFICIT HYPERACTIVITY DISORDER) IN A SECONDARY CARE SETTING**

1R Jaine, 2B Wilkins, 1–2C Yemula. 1Department of Paediatrics, University Hospitals of Birmingham NHS Trust, Solihull, UK; 2Department of Paediatrics, Union Street Clinic, Bedford, UK

Aims As most clinicians have limited experience and are still not confident about using Guanfacine since its license in 2016 in UK, this study was undertaken to identify any emerging themes—any gender differences, comorbid factors and side effects which could impact on its usage.

Method Data was collected from clinical notes on all our patients on Guanfacine over the past one year. This study looked at demographics, co morbidity, tolerance and dosage needed.

Emerging themes were identified in addition which could inform future studies on use of Guanfacine.

Results Age range 4–15 years (12 girls and 58 boys) received treatment with Guanfacine. Comorbidity was seen in 48 patients (69%): Autism spectrum disorder was commonest (16), Developmental coordination disorder (13), Leaning disability (10) some had other conditions e.g. Conduct disorder, tic disorder, dyslexia.

Guanfacine was discontinued in 36 patients (51%), the commonest side effect was sedation in 20 patients (29%) and other reasons for discontinuation included headaches, aggressive behaviour and ineffective control of ADHD symptoms.

The success rate was 98.8% in teenage girls.

The dose range was 1 mg (19) to 6 mg (1), and most patients (36) needed 2 to 3 mg for effective control of symptoms.

Conclusion It is small observational study and would be useful to have larger studies comparing the side effects and efficacy of low dose Guanfacine in teenage girls specifically across different regions.

Recommendations Low dose polytherapy regimes along with stimulant medication which would minimise side effects and improve overall efficacy should be explored in UK as is proven to be effective in other countries.
Aims This innovative process was undertaken to examine the most effective route to ensure that young people consistently received evidenced-based cost-effective treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Method A formulary approval pathway was developed for ADHD medication, following consultation, for a consistent approach.

A Specialist expressed interest in medication was reviewed by the formulary team, which involved a series of questions to be answered:

- Demonstrates evidence of benefit to the recipient and the health economy.
- Is there a strong evidence base for medication?
- In what cohort of young people should the medication be used?
- If accepted, would the medication be initiated or continued in primary care by General Practitioners (GPs), where a shared care protocol would be developed to ensure the roles and responsibilities of the specialist, GP and patient were clear to ensure appropriate prescribing and monitoring.

Results Following this appraisal, a positive evaluation and subsequent approval from the National Health Service (NHS) resulted in submission of application to the Area Prescribing Committee (APC) covering 3 cities, UK. The APC consists of varied healthcare individuals including the original sponsor to assess the formulary application and reach an informed decision. Once successful the medication is colour coded:

- Green enables all prescribers in health care to prescribe without restriction.
- Amber defines that initiation is performed by specialists in secondary care setting and prescribing transferred to GPs when the medication has been stabilised.
- Red requires initiation and maintenance only by the specialist.

Conclusion This pathway for the approval of medication to treat ADHD was designed in order to provide a consistent process and enable young people to receive evidence-based cost-effective treatment. This enables clinicians to have a transparent process across different health care settings.

Recommendation This approach can be transferred across regions in NHS (National health service) and would be useful to compare in future the processes in other regions/countries. An audit across the three cities and survey of clinicians about it would be useful to inform other practices.